Analyst Ratings January 26, 2026

BMO Sticks With Outperform on Celestica Ahead of Q4 Results, Cites TPU Upside and Hyperscaler Demand

Analyst reiterates $370 target as Celestica prepares to report Q4 2025 results on January 28; TPU outlook and hyperscaler spending seen as key drivers

By Ajmal Hussain CLS
BMO Sticks With Outperform on Celestica Ahead of Q4 Results, Cites TPU Upside and Hyperscaler Demand
CLS

BMO Capital has maintained its Outperform rating and $370 price target on Celestica (CLS) ahead of the company's fourth-quarter 2025 results, citing a stronger outlook for the company's TPU business and ongoing hyperscaler capital expenditure as potential catalysts for upside into fiscal 2026. Celestica has posted double-digit revenue growth and substantial share-price gains over recent periods, while other firms have also raised targets and highlighted governance changes on the board.

Key Points

  • BMO Capital reiterates Outperform and a $370 price target on Celestica ahead of Q4 2025 results due January 28.
  • Firm cites stronger TPU business outlook and sustained hyperscaler capital expenditure as potential catalysts for upside into fiscal 2026.
  • Celestica has shown 22.09% revenue growth over the last 12 months and delivered significant stock returns - 149.07% over one year and 78.06% over six months; other firms have raised targets and highlighted the company as a top large-cap tech pick.

BMO Capital has reaffirmed its Outperform recommendation on Celestica (NYSE: CLS) and kept a $370.00 price target in place as the electronics manufacturing services provider approaches its fourth-quarter 2025 earnings release scheduled for January 28. The firm notes that its $370 target remains below an analyst high of $420, yet it sits meaningfully above the companys most recent share price of $307.93.

In its assessment, BMO expects Celestica to deliver a solid fourth quarter and identifies a stronger-than-anticipated outlook for the company's TPU business as a potential source of upside for fiscal 2026 performance. The research note highlights Celesticas recent top-line momentum, with revenue up 22.09% over the past 12 months.

BMO points to sustained strength in hyperscaler capital expenditure spending, along with Celesticas customer exposure and competitive positioning, as factors that could contribute to further stock appreciation over the next 12 months. The firm characterizes the current valuation as attractive relative to the company's growth profile, improving margins, and the possibility that estimates could be revised higher.

Celestica is described in the research as a provider of design, manufacturing, and supply chain services across multiple industries, with increasing emphasis on higher-growth segments such as artificial intelligence infrastructure components. The stock has delivered pronounced market returns recently, recording a 149.07% price return over the past year and a 78.06% gain over the last six months.

Additional analysis available through InvestingPro points to 13 supplementary insights on Celesticas financial condition, with the company's financial health rated as "GOOD" and assigned a score of 2.95.

Other broker commentary has also shifted upward. Aletheia Capital raised its price target for Celestica from $330 to $410 while maintaining a Buy rating, a move the firm tied to expectations for a notable rise in earnings per share between fiscal 2025 and 2027 driven by growth across the company's business segments.

Separately, BMO Capital Markets named Celestica and Shopify as top large-cap selections in Canadian technology for 2026, highlighting both companies for their competitive positions and robust growth trajectories. BMO observed that Celestica has produced triple-digit returns for three consecutive years and continues to grow faster than other large-cap names the firm covers.

On the governance front, Celestica announced board changes, including the planned resignation of Dr. Luis Mfcller from his role as chair of the audit committee and from other board positions. Dr. Mfcllers resignation is effective January 28, 2026, and the company said the departure is for personal reasons and not the result of any disagreements with management or the board.

Taken together, these analyst views, target adjustments, and board developments underscore active strategic and operational shifts at Celestica as it heads into the new fiscal reporting period.

Risks

  • Earnings outcome risk - the company's Q4 2025 results, scheduled for January 28, may differ from BMO's expectation of a solid quarter, which could affect near-term stock performance - impacts technology and manufacturing sectors.
  • Estimate sensitivity - upside to fiscal 2026 depends partly on a stronger TPU outlook and potential revisions to estimates; if TPU demand or performance falls short, expected earnings and valuation re-rating may not materialize - impacts semiconductor and AI infrastructure supply chains.
  • Governance change uncertainty - the announced resignation of Dr. Luis Mfcller from the audit committee and the board, effective January 28, 2026, introduces a degree of leadership transition that could affect investor perception during strategic adjustments - impacts corporate governance considerations across the company.

More from Analyst Ratings

Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026 Needham Lifts Napco Security Price Target to $49 After Robust Q2 Results Feb 2, 2026 Evercore ISI Sticks with Outperform on Apple, Sets $330 Target Backed by App Store and Services Strength Feb 2, 2026 Deutsche Bank Says AppLovin Risk-Reward Looks Better After Google’s Project Genie Shock Feb 2, 2026